The present invention relates to a novel polymorphic form of Rotigotine characterized by at least one of the following X- ray powder diffraction peaks: 12.04, 13.68, 17.72 and 19.01 � 0.2 (�2?), measured with a Cu-Ka irradiation (1.54060 �), and a process for production thereof, which is useful for the manufacture of a stable medicament for treating or alleviating symptoms of Parkinsons Disease and other dopamine-related disorders.
